drugset / Trial / NCT04889716
CAR-T Followed by Bispecific Antibodies
Phase 2
Active not recruiting
23 enrolled
Abramson Cancer Center at Penn Medicine
Genentech, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
Timeline
- Start
- 2021-11-05
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glofitamab | Monoclonal antibody | 30 mg | Intravenous |
| Subject | Mosunetuzumab | Monoclonal antibody | 30 mg | Intravenous |
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |